AryoGen
AryoGen Pharmed (Persian: آریوژن فارمد) is an Iranian biopharmaceutical company specializing in manufacturing Therapeutic Monoclonal antibodies and some other recombinant proteins.[1][2][3]
History
AryoGen is a biopharmaceutical company created on the mandate of Iranian executive branch. It was spun off a Biopharmaceutical company, which formed a new entity named AryoGen Pharmed which started its production in 2011. It was deemed an issue of national interest. AryoGen changed its name to AryoGen Pharmed in 2016.
AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified.[4]
Products
AryoGen's products include:
- Blood Coagulation factor VII with the name of AryoSeven
- Altebrel with the generic name of Etanercept and original trade name of Enbrel
- Zytux with the generic name of Rituximab and original trade name of Rituxan
- َAryoTrust with the generic name of trastuzumab and original name of Herceptin
- Stivant with the generic name of bevacizumab and original trade name of Avestin
AryoSeven is now approved by Iranian food and drug organisation and from August 2012 is in the market.
See also
References
- ^ "IRAN, ISLAMIC REPUBLIC OF : Aryogen produces locally made medicines in Iran; helps Iran save up to $100 mln annually". Mena Report. Archived from the original on 2014-10-01.
- ^ World's 2nd factor VII factory opened in Iran. - Mehr News Agency (MNA) | HighBeam Research
- ^ Iran launches domestic manufacture of anti-hemophilia drug - Trend.Az
- ^ "MENA mAb manufacturer AryoGen receives EU GMP approval / Pharma News / Home - GaBI Online - Generics and Biosimilars Initiative". www.gabionline.net. Retrieved 2019-06-11.
